Supplementary Figure 1 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer

Key Points

• ERBB2 mutations and copy number amplifications were identified, highlighting potential biomarkers for treatment response.
• The analysis focused on ctDNA and metastatic tissues, revealing critical insights into cancer genetics.
• Findings suggest that monitoring ERBB2 alterations in ctDNA may inform therapeutic strategies.
• The study emphasizes the importance of assessing genetic changes in metastatic urothelial cancer.